Apixaban for extended treatment of venous thromboembolism.

By G. Agnelli, H. Buller, A. Cohen, M. Curto, A. Gallus, Margot Johnson, A. Porcari, G. Raskob, J. Weitz. New England Journal of Medicine, 2013

1,268 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology, Internal Medicine

View Paper: https://www.semanticscholar.org/paper/7377c1e03a998d56ecb58fc6c3ef93b159cc03e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

In Hematology

S. Konstantinides

In Internal Medicine

Citations in the corpus

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. (2020, background): “5 mg twice daily for apixaban.(306,314) The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arth”
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “apixaban, and edoxaban), and secondary prevention of deep venous thrombosis or pulmonary embolism (rivaroxaban and apixaban only) [119–128].”
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. (2020, neutral): “New England Journal Of Medicine, 382(17), 1599-1607.”
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. (2013, background): “1% (5 mg).(58) Additional concerns with using these agents in patients with cancer include: unpredictable absorption and higher risk of GI bleeding in those with mucositis or other GI complications, altered metabolism in those with liver or renal impairment, drug interaction with hormonal and chemot”
ESC Guidelines on the diagnosis and management of acute pulmonary embolism (2014, background): “5 mg or 5 mg twice daily) or placebo.(371) Patients were eligible for inclusion if there was clinical equipoise regarding”
Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. (2012, methodology): “5 mg twice daily is used for extended therapy.(48)”
[2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. (2014, neutral): “5 mg or 5 mg twice daily) or placebo.(371) Patients were eligible for inclusion if there was clinical equipoise regarding the continuation or cessation of anticoagulation therapy.”
2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS) (2019, background): “) should be considered after 6 months of therapeutic anticoagulation.(352,353) IIa A”